Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease

Study achieved key objectives for safety, efficacy and pharmacokinetics After completion of the study, all patients enrolled in an extension study pegunigalsidase alfa (PRX-102) provided coverage to patients for the entire 4-week period in treated pa... Biopharmaceuticals Protalix BioTherapeutics, Chiesi , Fabry disease, pegunigalsidase alfa
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news